




We will produce ultra-premium quality veganic cannabis at low cost & with low environmental impact.



The Problem

Pesticides, chemical fertilisers & heavy metals in cannabis crops are common & high levels are transferred into smoke & edibles.

Even organic cultivation uses animal derived inputs which contain heavy metals.

Cultivation is costly, energy intensive & requires a large amount of water.

The Solution

We will produce ultra-premium quality cannabis with zero residues using vegan-organic cultivation.

Our facility will use geothermal climate control and 90% less water for minimum environmental impact.

Our costs will be up to 65% less than most producers.



Why Veganic?

Cannabis plants are hyper accumulators – They draw up all contaminants from soil into their leaves & flowers which is transferred to the end product & toxic when smoked or ingested.

Animal derived fertilisers and even seaweed used in even organic cultivation contain heavy metals.

Recent research showed that regular cannabis users had 27% higher levels of lead & cadmium in their blood and urine than non-users.

Veganic cultivation uses only plant-based fertilisers that do not contain heavy metals and is the logical way to create a pure end product.

Veganic cultivation also enables higher yields and lower costs when plant fertilisers are grown on site.





The Product

Ultra-premium quality veganic EU GMP & GACP certified medical & recreational cannabis dried flower.

Own strains to gain IP, treat specific medical disorders and delight the cannabis connoisseur.

Cultivated using organic living soil and no animal-derived inputs – making it veganic.

Why Now?

Industry is still in its infancy and presents a unique opportunity for growth over the next 5-10 years.

Big pharma, tobacco and alcohol are entering the market.

Veganic cannabis is poised to become a strong niche market as awareness of the benefits increase.

Cannabis is going mainstream.



Market Size

The cannabis market is one of the largest industry opportunities worldwide.

The global cannabis market size was valued at \$57.18 billion in 2023 and is forecast to grow to \$444.34 billion by 2030, at a CAGR of 34.03%.



LOCATION:

Portugal – Has Licensing Opportunity, Ideal Climate & Inexpensive Land.

PRODUCT:

Ultra-premium veganic pharmaceutical grade EU GMP/GACP certified cannabis dried flowers.

Business Model

REVENUES:

Y1 yield target = 3,768kg of dried cannabis flowers to create revenues of £11.2M.

Price Point: wholesale price of £3.27 per gram for premium veganic medical cannabis.

ROUTE TO MARKET:

Initially through distributors then direct to dispensaries.

The Technology

Advanced Fully Sealed Hybrid Greenhouses Enabling:

Increased quality & yield.

Decreased crop contamination/disease.

EU GMP / GACP compliance.

Reduced energy costs by up to 65% through geothermal powered HVAC system.

90% less water consumption.





Traction

World Class Team and Advisors on board.

Land Identified / Opportunity to Purchase Site with Ideal Infrastructure.

Meetings held with distributors who are keen to work with us.

All Suppliers & Consultants Ready to Engage.

Competition

Numerous medical cannabis producers globally but demand exceeds supply.

61 Licensed companies in Portugal (California has 8,600, Portugal is 22.8% in size).

Our veganic production, ultra-premium quality & low-cost sustainable production will create strong differentiation.



Initial sales through
distribution partners.

Meetings held with European,
UK and Israeli distributors
keen to work with us.



**Route to
Market**

Own distribution in Y3.

Vertical integration in Y5:
Medical product development,
consumer outlets Etc.

Financial Forecast Snapshot

| | Y1 | Y2 | Y3 | Y4 | Y5 |
|-------------------------|-------------|-----------|------------|------------|------------|
| Turnover | 0 | 5,040,778 | 11,201,730 | 26,884,147 | 51,527,949 |
| Direct Costs | 0 | 82,560 | 41,280 | 123,840 | 227,040 |
| Gross Profit | 0 | 4,958,218 | 11,160,450 | 26,760,307 | 51,300,909 |
| Overheads | 1,548,353 | 3,957,490 | 3,043,389 | 11,018,383 | 15,970,641 |
| Net Profit | (1,548,353) | 1,000,728 | 5,232,177 | 15,741,924 | 35,330,268 |
| Corporation Tax | 0 | (136,906) | 1,308,046 | 3,935,482 | 8,832,571 |
| Profit After Tax | (1,548,353) | 1,137,634 | 3,924,131 | 11,806,442 | 26,497,697 |
| Margin | N/A | 22% | 35% | 44% | 51% |

Additional revenues from recreational use cannabis market and other diversification will be obtainable.

The Rogida Medical Team

70 years of senior management experience.

Over 30 years in large scale commercial cannabis cultivation.

10 years in global cannabis advisory services.

20 years in technology & data operations.

Our Advisory Board includes Leading Experts in Licensing & Compliance (Portugal), Cannabis Science, Organic Cultivation & Pharmaceutical Quality Assurance.

Combined they bring 100 years of experience to the business.



Leadership - Gideon and Daniel have worked together for decades and have built a strong friendship with Cameron.



Gideon Elichoff FLS

Co-founder & CEO

Gideon has 30 years management experience at board level in service and technology industries. He has private equity, VC and AIM funding experience and has worked with a number of Fortune 500 companies, academia and the UK government within the sustainable development sector.



Daniel Connell

Co-founder & COO

Daniel has 20 years' experience in senior operations management in the leisure, construction and technology sectors and has worked with several Fortune 500 companies. Daniel also has broad experience in web development, social media marketing and client relationship management.



Cameron Bravmann


Co-founder & CCO

Cameron is a highly acclaimed expert in commercial cannabis cultivation and has been involved in the industry for 30 years. He has been a part of license winning teams in over a dozen US states, and has designed, built, and operated over 100,000 m2 of cultivation operations internationally.

Capital Requirement & Use of Funds (Seed)

Initial seed funding: **£300,000** to enable:

-  Incorporation of Portuguese company and associated costs = **£5,750**
-  Land purchase in Portugal – 80,000M² = **£150,000**
-  License application, EU GMP/GACP certification and SOP verification = **£25,000**
-  Ceres schematic design (Hybrid Greenhouses) = **£42,000**
-  Preparation of Marketing Collateral etc. for second Round of funding = **£25,000**
-  Professional fees, Travel, accommodation, expenses and all other Costs = **£52,250**



Investment Opportunity

The cannabis industry is still embryonic.

Rogida Medical offers investors potentially high ROI in a financially sustainable business & production model.



£250k as SEIS/EIS Seed Round (target £300k) - **X25 ROI** obtainable by Y5.



£14.1m (inc Seed) full requirement including 30% headroom – **X7 ROI** obtainable by Y5.



Exit: An IPO option, trade sale or MBO is anticipated at year 5 when the valuation is forecast at £257.6 million (based on x5 multiple of Y5 turnover).



A more aggressive expansion will be possible at the end of year 5 which can enable Rogida to obtain a '**UNICORN**' valuation by year 9.

Comments about Rogida Medical:

“If all of the statements and assumptions prove to be accurate, you will have a successful business and will be among those left standing when other companies with poorer business plans fail”.

David Hyde - Director at www.hydeadvisory.com, trusted advisors to the cannabis market.

“Cannabis companies in Portugal are struggling to cultivate high quality cannabis. Rogida’s planned grow environment, technology and team are impressive and must be one of the best concepts I have seen. I believe their assets will enable them to achieve their target premium quality and know distributors who would be keen to purchase from them”

Giles Parker - Director at www.groweriq.ca, cannabis software and consultants.



Thank you from us all at Rogida Medical for taking time to look at our deck.

Our business plan and 5-year financial forecasts are available on request.

Gideon Elichao - Co-Founder & CEO

gideon@rogida.com

+44 (0)7741 890001

<https://rogida.com>

